Conference Call with Granules India Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Granules India announced Q3FY25 results The Company voluntarily paused the production at the Gagillapur plant in Sep-24 for risk assessment on account of the US FDA observations. Subsequently, the production resumed in October in a staggered manner. Revenue from Operations of Q3FY25 stood at Rs 11,377 million, a decline of 2% YoY. Revenue share from North America increased to 77% in Q3FY25, compared to 66% in Q3FY24. Finished dosages (FD), Active Pharmaceuticals Ingredients (API) and Pharmaceutical Formulation Intermediates (PFI) contributed 76%, 12%, and 12% of revenue from operations respectively for Q3FY25. ROCE for Q3FY25 is at 16.4% as compared to 15.3% for Q3FY24. Net debt stood at Rs 8,289 million. and Net debt to EBITDA ratio was 0.90 Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited said, “We continue to sustain our profitable growth in the finished dosages segment, driven by our North America business. We are enhancing quality and compliance through systemic improvements across our operations, including Gagillapur. Progress on our greenfield formulation expansion at GLS remains on track, reinforcing our capabilities and driving future growth.” Result PDF